Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.05.29.20117184: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Model Structure: Using Microsoft Excel (Microsoft Corporation, Redmond, WA) with the Crystal Ball add-in (Oracle Corporation, Redwood Shore, CA), we developed a computational model (in 2020) representing the U.S. population (357,157,434 persons) and their different interactions with each other as well as the spread of SARS-CoV-2 and the potential health and economic outcomes7. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature…
SciScore for 10.1101/2020.05.29.20117184: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Model Structure: Using Microsoft Excel (Microsoft Corporation, Redmond, WA) with the Crystal Ball add-in (Oracle Corporation, Redwood Shore, CA), we developed a computational model (in 2020) representing the U.S. population (357,157,434 persons) and their different interactions with each other as well as the spread of SARS-CoV-2 and the potential health and economic outcomes7. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations: All models, by definition, are simplifications of real-life and cannot account for every possible outcome.29 Our model inputs drew from various sources, and new data on SARS-CoV2 continues to emerge. The course of an actual COVID-19 coronavirus epidemic may not conform to our model data and assumptions. For example, we assumed individuals mixed equally with each other, and that individuals would be vaccinated by a certain day during the epidemic; however, in reality, individuals may be vaccinated at different time points over the epidemic. Moreover, assumptions about levels of herd immunity required may depend on differing individual susceptibility to SARS-CoV-2. Conclusions: Our study found that to either prevent or largely extinguish an epidemic without any other measures (e.g., social distancing), the vaccine has to have an efficacy of at least 70% when vaccination occurs within 90 days of the start of the epidemic and covers at least 60% of the population. This efficacy threshold increases the deeper one goes into the pandemic. A vaccine with an efficacy between 40% and 70% can still obviate the need for other measures under certain circumstances such as much higher, and potentially unachievable, vaccination coverages.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
